|Bid||19.52 x 1000|
|Ask||19.60 x 900|
|Day's range||19.28 - 20.64|
|52-week range||17.01 - 78.92|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.29|
FRIENDSWOOD, Texas, May 24, 2022--Castle announced new data showing that its TissueCypher® test outperformed standard of care in predicting progression in Barrett’s esophagus patients.
NEW YORK & FRIENDSWOOD, Texas, May 20, 2022--Research to Prevent Blindness and Castle are partnering to increase opportunities for medical students to gain research experiences in ocular cancer.
FRIENDSWOOD, Texas, May 19, 2022--New data presented at ACMS confirms independent risk-stratification performance of Castle's DecisionDx®-SCC test.